We recently compiled a list of 10 Best Fortune 500 Stocks to Buy Right Now. In this article, we will look at where CVS Health Corp. (NYSE:CVS) compared to other Fortune 500 stocks.
Should Investors Be More Cautious?
The total revenue of Fortune 500 companies in 2023 reached a record $41 trillion, rising by 0.1% annually. Profits also rose by 2% after a decline earlier in 2022. The US took the lead from Greater China with the most companies in the Fortune 500 list for the first time since 2018. It has 139 companies as of August this year, an increase of 3 from. 2023, while Greater China has 133 companies, down 9 from last year.
The financial sector, including banks and insurance companies, led all industries with the most Fortune 500 companies. Together the tech giants contributed $282 billion , up from $233 billion last year. Now, 13 companies are making their Fortune 500 debut, showing the world’s interest in AI and weight loss drugs.
While the S&P 500 has recouped most of its losses, the pullback has been led by sectors such as real estate, utilities and consumer goods rather than big tech companies. Investors are focusing on concerns about economic growth and expectations of a Fed rate cut.
However, it seems that investors think that even though investment portfolios should vary according to the current economic conditions, this opinion does not mean to exclude technology products, which of course contribute a lot to the total income of the Fortune 500. Jason Draho, UBS Global Wealth Management’s head of Americas Asset Allocation, emphasized this view and we mentioned this earlier in our article about 10 Best Tech Stocks to Buy Right Now Under $10:
“…investors should view potential declines in technology stocks as good long-term buying opportunities, as 10% corrections are good historical data of entering technology … He thinks that this market volatility is acyclical. The recent sell-off in the technology sector was not primarily caused by economic problems but by specific issues. However, the tech giants will continue to benefit from the AI CapEx investment story. While there may be short-term problems, the long-term outlook for these companies still good… Draho also cautioned against too many portfolios in the sector. He recommended diversification by investing in sector leaders as well as companies that could benefit. in tech disruption as a way to manage potential risks in tech stocks.”
Just last week, Dan Greenhaus, chief strategist at Solus Alternative Asset Management discussed the markets, and the staying power of the rebound, as he suggested that predicting that the Fed would leave more difficult.
He spoke about the continuing concerns of the recession, especially after the negative comments from the financial representatives. Despite these concerns, he believes that the US consumer is doing well, the economy is stable, and corporate profits are exceeding expectations. This fact suggests that the recent sell-off in AI stocks was followed by a reasonable return, as the issues seem to be limited to recent trends.
The S&P 500 is currently facing resistance around the 5,600 level, which is an important point for investors. Dan Greenhaus noted that the recent shift in the yield curve has raised concerns but the 2-10 year horizon is slightly positive. Despite these concerns, credit spreads for investment-grade bonds remain stable, and general stock indicators suggest a stable market environment.
Recently, discussions about potential interest rate changes have intensified, especially following comments from Goldman Sachs CEO David Solomon. He pointed to a 25 basis point cut by the Federal Reserve, although he also acknowledged the possibility of a 50 basis point cut. Greenhaus believes that the Fed will choose to cut the rate by 25 basis points, marking the beginning of a series of reductions. . This view is supported by normal inflation and a weak economy.
According to Greenhaus, parts of the stock market cycle appear to be performing well, indicating that the overall economic fundamentals are still strong, and there is no concrete case for any such situation. rate specific. As Fortune 500 companies continue to generate revenue and profits, investor sentiment should not change much. That being said, we are here with a list of the 10 best Fortune 500 stocks to buy right now.
Method
We started by looking at the list of Fortune 500 companies, as of 2024. We then selected 10 stocks from these Fortune 500 companies that were famous for the most among the top hedge funds and that analysts were continuing. The stocks are ranked in ascending order of the number of hedge funds that own shares in them, as of Q2 2024.
Why are we interested in the stocks that hedge funds accumulate in? The reason is simple: our research has shown that we can outperform the market by mimicking the best hedge fund options. Our quarterly strategy picks 14 small and large stocks each quarter and has returned 275% since May 2014, outperforming its benchmark by 150 percent (syes more details here).
A series of shelves in a supermarket, displaying different types of drugs and products for sale.
CVS Health Corp. (NYSE:CVS)
Market Capitalization as of September 14: $72.86 billion
Number of Hedge Fund Holders: 60
CVS Health Corp. (NYSE:CVS) is a health care company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many others. It is the world’s second largest health care company that operates multiple businesses, including retail pharmacies, health insurance plans, and specialty pharmacy services.
In its Q2 2024 results, the company revised its full-year earnings forecast downward due to challenges in its Health Care Benefits division, which includes its insurance division, Aetna. This marks the second time it has revised its 2024 forecast, having previously lowered guidance following its Q1 results for similar reasons.
However, the company still reports an annual revenue improvement of 2.60% in FQ2 2024. Revenue was $91.23 billion, while earnings per share were $1.83. Traders still expect to return as we see that 60 hedge funds is a long time. The highest value is $764,023,075 per Pzena Investment Management.
The company serves more than 186 million people. The company also grew Aetna medical members using CVS pharmacies to 9 million, an 8% increase, and 13.8 million Aetna members are now covered. by Caremark, an increase of 13%.
CVS Health Corp. (NYSE:CVS) is positioned for long-term success, driven by its innovative strategies and integrated healthcare model. The company is accelerating growth by implementing transparent pharmacy reimbursement systems like CVS CostVantage, increasing biosimilar acceptance, and improving patient outcomes through its integrated health care delivery portfolio.
Ariel Global Fund stated the following about CVS Health Corporation (NYSE:CVS) in its Q2 2024. investor letter:
“America’s health company, CVS Health Corporation (NYSE: CVS ), also declined after disappointing earnings results and a subsequent cut in full-year guidance. The error was primarily due to increased utilization of Medicare Advantage plans and weakness in the health services segment resulting from the loss of a large customer and continued improvement in pharmacy customer pricing. In response, executives refocused their attention on improving the network and improving their position in Medicare Advantage. CVS believes the program can remain an attractive business for Aetna and CVS Health over time, and will frame its proposal for 2025 as a multi-year opportunity to bill benefits across and plan level benefits. Meanwhile, CVS continues to return cash to shareholders through dividends and recent rapid stock sales.
Overall CVS 10th position on our list of the best Fortune 500 stocks to buy. While we acknowledge the potential of CVS as an investment, our confidence lies in the belief that AI stocks have the greatest promise to deliver high returns and do so in the short term. If you’re looking for an AI stock that’s more promising than CVS but trades for less than 5 times its earnings, check out our report on low price of AI stock.
READ NEXT: The $30 Trillion Opportunity: 15 Best Humanoid Robots to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA Has ‘Become A Ruin’.
Description: None. This article was originally published on Insider Monkey.
#CVS #Health #Corp #CVS #Among #Stocks #Buy